Higher Imatinib Dose Better in GIST Pts With Exon 9 Mutation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 6
Volume 15
Issue 6

A higher, investigational starting dose of imatinib (Gleevec) significantly improved progression-free survival (PFS) in high-risk patients with advanced KIT-positive gastrointestinal stromal tumor (GIST) expressing the exon 9 mutation, according to a new analysis of an EORTC phase III trial. The trial compared imatinib at the standard dose of 400 mg/d vs 800 mg/d in patients with unresectable and/or metastatic GIST. Researchers analyzed pretreatment GIST samples for mutations from 377 patients in the trial.

LEUVEN, Belgium—A higher, investigational starting dose of imatinib (Gleevec) significantly improved progression-free survival (PFS) in high-risk patients with advanced KIT-positive gastrointestinal stromal tumor (GIST) expressing the exon 9 mutation, according to a new analysis of an EORTC phase III trial. The trial compared imatinib at the standard dose of 400 mg/d vs 800 mg/d in patients with unresectable and/or metastatic GIST. Researchers analyzed pretreatment GIST samples for mutations from 377 patients in the trial.

The presence of a KIT exon 9 mutation was the strongest adverse prognostic factor for response to imatinib, increasing relative risk of disease progression by 171% (P < .0001), compared with KIT exon 11 mutations. In patients with the exon 9 mutation, the higher dose resulted in superior PFS (P = .0013), with a relative risk reduction of 61% (Eur J Cancer 42:1093-1103, 2006).

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.